Novartis AG Common Stock (NVS)

SG&A Expenses

$13.13B

TTM · Period ending: · USD

NVS logo

NVS SG&A Expenses

Latest reported$13.13B
NVS TTM SG&A Expenses ($1.65B → $13.13B)
High-resolution chart · PNG

NVS sg&a expenses history

Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.

Novartis AG Common Stock SG&A Expenses — Trailing twelve months (TTM) (USD)
Period endingSG&A Expenses (USD)
13,126,960,000
13,325,739,000
13,243,739,000
13,309,000,000
13,135,000,000
12,784,000,000
12,566,000,000
12,509,000,000
12,466,000,000
12,466,000,000
12,517,000,000
12,820,000,000
12,665,000,000
13,155,000,000
13,776,000,000
14,014,000,000
14,696,000,000
14,869,000,000
14,886,000,000
14,825,000,000
14,626,000,000
14,240,000,000
14,197,000,000
14,178,000,000
14,308,000,000
14,525,000,000
14,369,000,000
14,868,000,000
14,580,000,000
14,490,000,000
14,444,000,000
14,081,000,000
14,498,000,000
14,809,000,000
14,997,000,000
14,794,000,000
14,516,000,000
14,359,000,000
14,192,000,000
14,239,000,000
14,302,000,000
14,270,000,000
14,247,000,000
14,327,000,000
14,429,000,000
14,638,000,000
14,993,000,000
15,804,000,000
15,913,000,000
15,871,000,000
16,452,000,000
16,316,000,000
16,728,000,000
17,294,000,000
17,290,000,000
17,453,000,000
17,753,000,000
18,045,000,000
18,049,000,000
18,030,000,000
17,385,000,000
16,431,000,000
15,797,000,000
15,181,000,000
14,845,000,000
14,689,000,000
14,331,000,000
13,846,000,000
13,856,000,000
13,989,000,000
14,097,000,000
14,093,000,000
13,859,000,000
13,523,000,000
13,259,000,000
12,923,000,000
12,666,000,000
12,302,000,000
11,930,000,000
11,724,000,000
11,621,000,000
11,522,000,000
11,544,000,000
11,359,000,000
11,008,000,000
10,718,000,000
10,660,000,000
10,132,000,000
10,025,000,000
9,823,000,000
9,325,000,000
9,964,000,000
9,531,000,000
9,300,000,000
7,136,000,000
4,073,000,000
2,143,000,000
1,720,000,000
1,720,000,000
1,720,000,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.